Villere ST Denis J & Co. LLC grew its stake in Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) by 201.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 71,778 shares of the company's stock after purchasing an additional 47,928 shares during the period. Villere ST Denis J & Co. LLC owned approximately 0.45% of Alpha Cognition worth $363,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. National Bank of Canada FI bought a new stake in shares of Alpha Cognition in the 4th quarter valued at approximately $69,000. Salem Investment Counselors Inc. bought a new position in Alpha Cognition in the 1st quarter valued at $230,000. Manatuck Hill Partners LLC purchased a new position in Alpha Cognition during the 4th quarter worth $395,000. Tudor Investment Corp ET AL bought a new stake in Alpha Cognition during the 4th quarter valued at $412,000. Finally, MYDA Advisors LLC bought a new position in shares of Alpha Cognition during the 4th quarter worth $589,000.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the company. Raymond James Financial raised Alpha Cognition to a "moderate buy" rating in a research report on Tuesday, March 25th. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Alpha Cognition in a research report on Friday, May 16th.
Get Our Latest Analysis on ACOG
Alpha Cognition Trading Down 1.2%
Shares of ACOG traded down $0.11 during trading hours on Friday, hitting $9.10. The company had a trading volume of 43,509 shares, compared to its average volume of 73,643. Alpha Cognition Inc. has a one year low of $3.75 and a one year high of $11.40. The business's fifty day moving average price is $8.10.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.38. The firm had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.50 million.
Alpha Cognition Company Profile
(
Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Featured Stories
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
